Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORM-12741 in Alzheimer's disease patients on acetylcholinesterase inhibitors
2010-022922-34Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ORM-12741 plus background acetylcholinesterase inhibitor with Placebo plus background acetylcholinesterase inhibitor (2 arms). Primary endpoints: Safety and tolerability of ORM-12741 and Efficacy on cognitive symptoms. Started Dec 2010; status: completed.
02
Drugs
ORM-12741
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-022922-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022922-34.